Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-1898 in Unresectable or Metastatic Acral Melanoma
NCT06359860Phase 2Recruiting
- Sponsor
- Beijing Scitech-MQ Pharmaceuticals Limited
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACC-1898 in acral lentiginous melanoma (ALM), sponsored by Beijing Scitech-MQ Pharmaceuticals Limited. Started Nov 2023; status: recruiting.
02
Drugs
ACC-1898
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT06359860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359860.